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Abstract
Purpose of Review Aortic valve disease is the most common
form of heart valve disease in developed countries. Imaging
remains central to the diagnosis and risk stratification of pa-
tients with both aortic stenosis and regurgitation and has tra-
ditionally been performed with echocardiography. Indeed,
echocardiography remains the cornerstone of aortic valve im-
aging as it is cheap, widely available and provides critical
information concerning valve hemodynamics and ventricular
function.
Recent Findings Whilst diagnostic in the vast majority of
patients, echocardiography has certain limitations including
operator variability, potential for measurement errors and
internal inconsistencies in severity grading. In particular,
low-gradient severe aortic stenosis is common and chal-
lenging to diagnose. Aortic valve imaging may therefore
be improved with alternative and complimentary
multimodality approaches.
Summary This review investigates established and novel tech-
niques for imaging both the aortic valve and the myocardial
remodelling response including echocardiography, computed
tomography, cardiovascular magnetic resonance and positron
emission tomography. Moreover, we examine how the
complementary information provided by each modality may
be used in both future clinical practice and the research arena.
Keywords Valve . Stenosis . Regurgitation .Magnetic
resonance imaging . Echocardiography . Computed
tomography . Positron emission tomography
Introduction
Aortic valve disease is the most common valvular heart dis-
ease in the developed world [1]. In particular, calcific aortic
stenosis is responsible for considerable morbidity and mortal-
ity [2]. Aortic stenosis (AS) was once thought to be related to
simple Bwear and tear^ as a result of advancing age but is
increasingly understood to be a highly regulated process with
some similarities to atherosclerosis. An initiating event is be-
lieved to cause endothelial damage, inflammatory cell infiltra-
tion and initiation of calcification. A progressive cycle of cal-
cium deposition in the valve leaflets then occurs leading to an
inexorable march towards severe aortic stenosis and the de-
velopment of symptoms and heart failure unless aortic valve
replacement (AVR) is performed [3]. Aortic regurgitation
(AR) is common in calcific aortic valve disease but may also
be caused by other pathology affecting the valve, such as
endocarditis, or the aortic root, causing functional regurgita-
tion as in hypertension, Marfan syndrome, annulo-aortic
ectasia, collagen vascular disease and aortic dissection.
In both aortic stenosis and regurgitation, imaging of the
aortic valve is critical in establishing a diagnosis, grading se-
verity and informing the timing of valvular intervention. In
addition, the importance of the myocardial remodelling re-
sponse to these forms of valve disease is increasingly appre-
ciated [4]. Aortic stenosis leads to a pressure-overloaded left
ventricle, resulting in the left ventricular hypertrophy (LVH),
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which normalises wall stress according to Laplace’s law. This
is initially adaptive, but decompensation eventually occurs
leading to the development of heart failure, symptoms and
adverse events. Current clinical guidelines suggest valvular
intervention in severe aortic stenosis when there is evidence
of LV decompensation as indicated by the development of
either symptoms or impaired LVejection fraction (EF) [5, 6].
However, assessment of symptoms in elderly patients who
often have multiple comorbidities can be challenging whilst
impairment of LV systolic function occurs late in the disease
process [7] and is often irreversible [8, 9]. There is therefore a
need for more objective assessments of the left ventricular
decompensation. Similarly, in aortic regurgitation, the left
ventricle dilates in response to chronic volume overload in
an eccentric hypertrophic response.With time, this decompen-
sation of this remodelling response also occurs, leading to
heart failure, symptoms and adverse events in the absence of
treatment. Current guidelines advocate valve replacement in
the presence of severe aortic regurgitation and symptoms or
when LV dilatation reaches certain thresholds.
In this review, we will describe how modern advances in
non-invasive imaging might optimise assessments of aortic
valve stenosis and regurgitation as well as how the left ven-
tricular remodels in response to those lesions. In particular, the
established role of echocardiography will be explored along-
side emergingmodalities such as computed tomography (CT),
cardiovascular magnetic resonance (CMR) and positron emis-
sion tomography (PET).
Aortic Stenosis
Echocardiography
Transthoracic echocardiography (TTE) is the clinical imaging
modality of choice for assessing aortic stenosis and has been
since in the 1980s when it supplanted invasive catheter-based
measurements. It is safe, non-invasive and widely available,
allowing direct visualisation of aortic valve anatomy (e.g. bi-
cuspid vs. trileaflet), function and hemodynamics whilst also
facilitating measurement of the left ventricular wall thickness,
cavity dimensions and both systolic and diastolic function.
Doppler echocardiography provides information on aortic
valve hemodynamics that is not readily available using other
imaging modalities. Simple assessments of both peak and
mean velocities through the aortic valve (Fig. 1) are used to
calculate peak andmean pressure gradients using the modified
Bernoulli formula as well as the aortic valve area (AVA) using
the continuity equation. The latter is flow independent and
therefore often essential for diagnostic accuracy particularly
in low-flow states [10]. Current guidelines recommend grad-
ing haemodynamic severity of aortic stenosis on the basis of
the combined information provided by the peak velocity (AV
Vmax), the mean gradient and the aortic valve area [5, 6].
Whilst this combined approach is effective in the majority
of patients, it leads to a wide spectrum of diagnostic categories
and the potential for clinical confusion. Other potential limita-
tions of echocardiography are also being increasingly appreci-
ated. Firstly, acquisition of diagnostic acoustic windows can be
impossible in certain patients as can perfect alignment of the
Doppler probe with the direction of maximal blood flow
through the valve. In both circumstances, measurement errors
will be introduced. Secondly, echocardiography may have dif-
ficulty in measuring the left ventricular outflow tract (LVOT)
diameter with accuracy: a key component when using the con-
tinuity equation to calculate the aortic valve area. Indeed, echo
often underestimates the LVOT diameter due to either calcifi-
cation or its elliptical shape, and as the measurement is
squared, even small errors become magnified substantially.
The continuity equation also relies on several geometric as-
sumptions that frequently do not hold true in aortic stenosis
(such as a circular outflow tract and laminar flow profile),
introducing further error. Finally, internal inconsistencies exist
in the severity thresholds established in the clinical guidelines.
An AVA of 1.0 cm2 is sensitive but less specific for severe
aortic stenosis and in fact corresponds to a mean pressure gra-
dient of 30–35 mmHg [11], rather than the 40 mmHg cut-off
recommended [5, 6]. This in part may explain why between 20
and 30 % of patients with moderate or severe aortic stenosis
have discrepant assessments of disease severity depending on
the echocardiographic marker assessed [4, 12].
Fig. 1 Echocardiographic assessment of a patient with severe aortic
stenosis. a Short axis view showing heavily calcified leaflets. b
Parasternal long axis view showing large calcium deposit on right
coronary cusp with restricted valve opening. c Right sternal edge
continuous-wave Doppler with aortic valve velocity >4 m/s,
corresponding with severe stenosis
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LV Function and Mass
Echocardiography-derived LVejection fraction is used in clin-
ical guidelines to reflect LV systolic function. Impairment in
the EF below 50 % is an indication for valve intervention as
these patients have a poor outcome without surgery [8, 13].
However, a fall in ejection fraction is an insensitive measure of
LV systolic dysfunction in the presence of concentric remod-
elling and hypertrophy. Indeed, approximately one third of
patients with aortic stenosis and a normal EF have significant
evidence of LV systolic impairment when assessed by other
methods [14]. These alternative markers include global longi-
tudinal strain measurements, which have been shown to be of
prognostic importance in patients with severe aortic stenosis
and a normal ejection fraction [15].
Patients with aortic stenosis invariably develop the left ven-
tricular hypertrophy as the LV remodels to normalise wall
stress. The degree to which this occurs is not well correlated
to the haemodynamic severity of stenosis and is an indepen-
dent predictor of outcomes [16, 17•]. The LV hypertrophic
response should therefore be assessed separately. Concentric
remodelling geometry [18] and severe LVH [19] have been
associated with mortality following valve replacement whilst
increased LV mass is associated with cardiovascular morbidity
and mortality in patients with asymptomatic severe AS [17•].
Importantly, recent evidence from 1656 patients in the SEAS
trial showed that LV mass index was an independent predictor
of cardiovascular events and all-cause mortality [20••].
Low-Flow Low-Gradient Subtypes
The most challenging patients are those with discordant pa-
rameters of severity, most commonly characterised by a low
AVA and low transvalvular gradient. As discussed, there are
several possible explanations for this including measurement
error and internal inconsistencies in guideline thresholds.
However, in many patients, the discrepancy will not be due
to error but instead reflect a low-flow status related to an array
of different factors. Low flow is usually defined by a stroke
volume (SV) index of <35 ml/m2 although this cut-off is
somewhat arbitrary.
Classical Low-Flow Low-Gradient AS
In patients with severe aortic stenosis and LV systolic dys-
function, the stroke volume is low due to reduced myocardial
contractility. As a consequence, the gradient generated over
the aortic valve is relatively low (mean gradient <40 mmHg)
but the valve area is small <1.0 cm2 (low-flow low gradient
with reduced EF severe AS). It is important to differentiate
this condition from Bpseudo-severe AS,^ where the ventricle
is severely impaired due to an alternative pathology to the
extent that it cannot generate sufficient flow to completely
open the aortic valve. Low-dose dobutamine stress echocardi-
ography (DSE), as recommended in clinical guidelines [5, 6],
can differentiate between these; if the mean valve gradient
increases to >40 mmHg (or AV Vmax >4 m/s) and valve area
remains <1.0 cm2 with dobutamine stress, then severe AS has
been identified. These patients have a relatively low operative
mortality (5–7 % [21, 22]) and benefit from AVR [23].
Flow Reserve
Those patients who fail to increase their gradient with stress
echocardiography likely have no or reduced Bflow reserve^
which is defined as an increase in stroke volume of less than
20 % [24]. This group of patients has significantly higher
operative mortality (22–30 % [13, 21]), but those who survive
AVR have outcomes (improvement in EF and mortality) sim-
ilar to those with flow reserve [13, 25] and an improved prog-
nosis compared to similar patients managed medically [13].
There may be an increased future role for transcatheter aortic
valve implantation (TAVI) in this group given their high op-
erative risk.
Paradoxical Low-Flow Low-Gradient AS
These patients have low flow in the context of preserved ejec-
tion fraction, again leading to a picture of a reduced AVA
(<1.0 cm2) and low mean gradient (<40 mmHg). It is often
referred to as low-flow low-gradient normal EF or paradoxical
low-flow low-gradient aortic stenosis andwas first identified in
2007 [26]. Commonly, these patients are female and elderly,
with a small hypertrophied LV cavity as the cause of their low
stroke volume. A recent meta-analysis of 7459 patients and
other studies have indicated that mortality is increased in this
group [26, 27••, 28, 29] and reduced by valve intervention
[28–31]. However, this has not been observed consistently in
all trials [32]. Stress echocardiography has not been shown to
be helpful in these patients as they often exhibit restrictive
physiology due to diastolic dysfunction limiting any increase
in SV; however, aortic valve CT calcium scoring may aid in
discrimination [12]. Current clinical guidelines recommend
aortic valve intervention in this group if the patient is symp-
tomatic and the clinician feels that valve obstruction is the most
likely cause of symptoms based on the above parameters [5, 6].
Normal-Flow Low-Gradient AS
Patients with both a low AVA and low mean gradient in the
context of preserved EF and normal flow are a common
[27••] but under recognised group who are not represented
in clinical guidelines. Although this is heterogeneous group
that encompasses measurement errors, small body size or
inconsistencies in clinical guidelines [11], a significant pro-
portion have severe AS [12] and AVR appears to improve
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survival [31]. A recent large meta-analysis has demonstrat-
ed that these patients have outcomes similar to high-
gradient severe AS which are improved by AVR [27••].
Further research in this area is required.
Dimensionless Index
The dimensionless velocity index is a flow-independent vari-
able calculated by dividing the LVOT velocity-time integral
(VTI, or Vmax) by the AV VTI (or Vmax) without a need to
measure the LVOT diameter. A ratio of <0.25 indicates severe
stenosis and is particularly useful where LVOT measurement
is difficult to perform or in cases of inconsistent grading [33].
Advanced Echocardiography
In addition to demonstrating flow reserve in low-flow low-
gradient severe AS with a reduced ejection fraction, stress
echocardiography has also been shown to improve prognosti-
cation in asymptomatic high-gradient severe AS where an
increase in mean gradient of >20 mmHg on exercise stress
predicts a greater risk of developing symptoms and adverse
events [34, 35].
Transoesophageal echocardiography (TOE) can be of
use in aortic stenosis with planimetry of the AVA used as
an alternative measure of aortic stenosis severity. Whilst
planimetry remains difficult on 2D imaging due to extensive
calcification and difficulty ensuring position at the leaflet
tips, it appears more readily feasible on 3D TOE. A study of
307 patients with severe aortic stenosis compared valve
planimetry using 3D TOE with TTE-derived aortic valve
area. They showed that valve planimetry was possible in
92 % of patients (in the 8 % where it was not possible, this
was due to severe calcification) and that the two measure-
ments showed a good correlation (r = 0.85). However,
planimetred AVA measurements were consistently higher
than those calculated with the continuity equation [36].
Adjudicating disease severity using planimetry can there-
fore be difficult although in that context, an AVA<1.0 cm2 is
a strong indication of severe aortic stenosis and a potentially
useful arbitrator in cases of diagnostic uncertainty.
TOE also offers accurate assessment of the aortic root and
annulus dimensions and is frequently performed preoperative-
ly before aortic valve surgery. Similar measurements can be
made with CT imaging and the modality used differs between
centres. The use of intraoperative TOE is routine in many
cardiothoracic centres where it allows accurate assessment of
anatomy and optimisation of hemodynamics before establish-
ing cardiopulmonary bypass. Post-procedure, TOE can con-
firm satisfactory valve function, stable hemodynamics and
exclude complications such as outflow tract obstruction. A
number of observational studies suggest that intraoperative
TOE changes management in 11–18 % of patients may
improve outcome [37, 38] and may be cost-effective [39].
Intraoperative TOE has a class lla recommendation from the
most recent CC/AHA/ASE 2003 Guideline Update for the
Clinical Application of Echocardiography.
Pre-procedural imaging (TOE or CT) is essential prior to
TAVI to ensure correct prosthesis sizing, and real-time intra-
procedural TOE is often used to aid in device sizing and po-
sitioning [40, 41], although this is limited to trans-apical and
aortic approaches where the patient is under general anaesthet-
ic. Studies are conflicting but suggest that there is overall a
slight overestimation of annulus area with CT and underesti-
mation with TOE [42, 43]. 3D TOE is superior to 2D TOE and
offers similar results to CT in some studies [44].
Valvular Calcification
Although the mechanisms underlying valvular calcification
remain incompletely determined [3], its importance to disease
progression and adverse events was first identified in the sem-
inal studies by Rosenhek and colleagues [45••, 46••]. One
hundred and twenty-six patients with asymptomatic severe
aortic stenosis were followed up for 22 ± 18 months. Aortic
valve calcification was measured on a four-point ordinal scale
with moderate or severe calcification (a score of 3 or 4) being
the only independent predictor of AVR or mortality,
outperforming haemodynamic measures of severity.
Significant valve calcification is also associated with faster
disease progression, need for AVR and all-cause mortality in
patients with mild to moderate stenosis [46••]. Whilst severe
aortic valve calcification is considered a lla indication for
AVR in asymptomatic patients with severe AS, this technique
is in practice difficult to apply because of poor intra-observer
agreement as to the severity of calcification [47].
CT
CT Calcium Scoring
Calcium burden in the aortic valve can be more accurately
quantified on electrographically gated non-contrast computed
tomography (CT). The aortic valve CTcalcium score can then
be measured using the Agatston score (AU), which accounts
for both the density and volume of CT measured calcium and
correlates closely with the weight of calcium in explanted
aortic valves [47]. Aortic valve CT calcium scoring has dem-
onstrated excellent intra- and inter-observer and scan-rescan
reproducibility [47, 48] and correlates closely with echocar-
diographic measures of haemodynamic severity [47–49].
Importantly, recent data has demonstrated that the aortic valve
CT calcium score provides powerful prediction of disease
progression and prognosis [50–52].
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Severity Cut-Offs
Thresholds in CT calcium score for differentiating moderate
from severe aortic stenosis have recently been proposed in a
study of 451 patients with concordant grading of AS severity
on echocardiography and preserved ejection fraction.
Interestingly, these were different for males and females
(≥2065 AU for men and ≥1274 AU for women) even after
indexing to the aortic annulus area (≥476 AU/cm2 for men and
≥292 AU/cm2 for women). These thresholds were then ap-
plied to a larger cohort of 794 patients and demonstrated a
strong predictive value for all-cause mortality of incremental
value to echocardiographic parameters of ejection fraction and
stenosis severity [53••] (Fig. 2).
Aortic valve calcium scoring may be of particular use in
cases of low-flow low gradient with reduced EF [49, 54],
especially in the absence of flow reserve [47] where it can
be challenging to determine severity by echocardiography
alone. Further work is required to assess the validity of these
thresholds in alternative patient populations and to confirm
their predictive value. If these prove confirmatory, then we
believe CT calcium scoring will emerge as a clinically useful
and flow-independent adjuvant to standard echocardiography.
Improved AVA Calculation
The increasing use of CTangiography for valve sizing prior to
TAVI procedures has demonstrated that the LVOT is often
eccentric not circular. Indeed, a recent study of 269 patients
with severe AS undergoing CT demonstrated that the LVOT is
eccentric in 93 % of patients [55]. As a consequence, TTE
measures of the LVOT diameter can frequently result in un-
derestimation of the true AVA [56]. Using CT, CMR or indeed
3D echo to planimeter the LVOTarea could therefore improve
the accuracy of AVA calculations.
PET
PET is a novel imaging technique, which allows the activity of
specific disease processes to be measured in vivo. Recently,
this technique has employed two tracers to measure inflam-
mation (18F-fluorodeoxyglucose (18F-FDG)) and calcification
activity (18F-fluoride) in the valves of patients with aortic ste-
nosis. Hybrid PET/CT scanners then allow the activity of
these two key processes to be compared with the presence of
established regions of macrocalcification on CT.
18F-Fluoride
18F-fluoride has been used as a bone tracer for 50 years binding
to hydroxyapatite crystal and detecting regions of increased
bone activity. In the vasculature, it binds preferentially to re-
gions of newly developing microcalcification because the sur-
face area of hydroxyapatite in these nanocrystalline regions is
at its highest. By contrast in regions of macrocalcification,
much of the hydroxyapatite is internalised and not available
for binding [57]. In aortic stenosis, 18F-fluoride acts as a mark-
er of calcification activity correlating with histological staining
for alkaline phosphatase (r = 0.65) and osteocalcin (r = 0.68)
[52] and predicts where novel regions of macroscopic calcium
are going to form (Fig. 3). Tracer uptake increases with more
advanced aortic stenosis [58], offers powerful prediction of
disease progression at 1 and 2 years, of small incremental value
to computed tomography [52, 59], and acts as an independent
predictor of adverse clinical events [59]. This technique holds
promise in better understanding the role of calcification in
aortic stenosis, for example, a recent PET study demonstrated
that whilst calcification activity in aortic stenosis is greater than
inflammation, the reverse is true in atherosclerosis, potentially
explaining the different effects of statins in these two condi-
tions [60]. With further improvement, 18F-fluoride PET may
Fig. 2 Survival of patients with aortic stenosis under medical treatment
according to valvular calcium score. Patients with severe absolute
calcification (a) or calcification indexed to body surface area (b) had
increased all-cause mortality compared to patients with non-severe
calcification. Indeed, severe aortic valve calcification (AVC) was an
independent predictor of survival following adjustment for age, sex,
presence of coronary artery disease or diabetes, indexed aortic valve area
and ejection fraction. Reproduced from Clavel et al. [53••] with
permission from Elsevier/Journal of the American College of Cardiology
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prove of clinical use in identifying patients likely to progress
rapidly towards surgery and as a marker of disease activity and
efficacy end point in clinical trials of novel therapies (e.g.
SALTIRE 2: NCT02132026).
18F-FDG
18F-FDG PET is widely used to image vascular inflammation.
This PET tracer is a glucose analogue, which accumulates in
metabolically active cells such as vascular macrophages.
Indeed, an excellent correlation between macrophage burden
on histology (CD68 staining on immunohistochemistry) in
carotid atheroma [61] and the 18F-FDG signal has been ob-
served. In aortic stenosis, 18F-FDG activity is higher in pa-
tients versus controls, demonstrating a modest correlation
with severity of valvular disease [58]. Of interest, no correla-
tion with CD68 staining of explanted valves was observed
suggesting that 18F-FDG uptake is occurring in other metabol-
ically active cells, although this study was limited by a low
sample size [52]. Perhaps, the biggest limitation of this tech-
nique is the effect of physiological myocardial 18F-FDG up-
take, which frequently contaminates signal originating from
the aortic valve.
CMR
Cardiac magnetic resonance is an emerging technology that
offers excellent spatial resolution, functional assessment and
the unique ability to provide myocardial tissue characterisa-
tion. However, it remains an expensive modality with limited
availability for cardiac patients in most centres,
LV Mass and Hypertrophy
CMR provides the gold-standard assessment of LV volumes
and mass and allows detailed investigation of both the degree
of hypertrophy and the different patterns of the left ventricular
adaption. Importantly, the myocardial hypertrophic response is
only weakly correlated with the hemodynamic severity of aor-
tic stenosis [16, 62, 63], with males generally display a greater
increase in LV mass even after correction for body size [16].
Classically, wall thickening occurs in a concentric pattern, but
recent studies have shown that asymmetrical patterns also exist
in around a quarter of patients assessed by CMR [16]. The
clinical importance of this observation remains unclear.
Myocardial Fibrosis
Myocardial fibrosis is a key mechanism driving the progres-
sion from the left ventricular hypertrophy to heart failure and
death in aortic stenosis [64]. Historically, it has only been
appreciated using invasive endomyocardial biopsy tech-
niques, but this carries a small but significant risk of compli-
cations [65] and is susceptible to sampling error. CMR pro-
vides a non-invasive assessment of whole-heart fibrosis using
two techniques: late gadolinium enhancement (LGE) and T1
mapping (Fig. 4).
LGE
This technique was first described in 1999 [66] and involves
the intravenous administration of gadolinium-based contrast
agents (GBCA). These agents alter myocardial T1 values and
enter healthy myocardium from the blood pool down a con-
centration gradient within 1–3 min (wash-in phase). Renal ex-
cretion of GBCA from the blood pool then produces a reverse
concentration gradient with myocardial GBCA concentrations
declining over the ensuing 10–30 min (wash-out phase). The
large molecular size of gadolinium stops GBCA from crossing
cell membranes, so that they effectively label the extracellular
space and accumulate in regions of replacement fibrosis due to
delayed wash-out [67]. These focal areas can then be detected
using T1-weighted sequences 15–20 min after contrast admin-
istration. In aortic stenosis, areas of replacement fibrosis appear
as bright areas in the mid-wall of the left ventricle in contrast to
surrounding healthymyocardium [68]. Areas of previousmyo-
cardial infarction, which are common in AS patients, are also
detected by this technique but can be differentiated from mid-
wall replacement fibrosis by their subendocardial/transmural
pattern and their coronary distribution.
Mid-wall replacement fibrosis as detected by LGE is com-
mon in aortic stenosis (29–62 % of patients depending on the
population studied [69, 70•, 71•]) and seems to be irreversible
following valve intervention [72]. The presence of LGE cor-
relates with histological fibrosis [73•] and evidence of
Fig. 3 18F-fluoride PET activity predicts the development of new
calcific deposits in the aortic valve on repeat CT imaging performed
after 1 year. Example imaging from two patients (a and b) are shown
below. Baseline non-contrast CT images (left) showed evidence of in-
creased 18F-Fluoride PET activity (middle) in areas where subsequent
calcification was observed on repeat CT scanning after 1 year (right).
Reproduced from Pawade et al. [3] with permission from Elsevier/
Journal of the American College of Cardiology
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myocardial injury (as measured by high sensitivity troponin I
concentrations) [74]. Advanced mid-wall fibrosis identifies
patients that do not gain improvement in LV systolic function
[73•] or overall functional status following AVR [72].
Importantly, three studies have confirmed that the presence
of LGE acts as an independent predictor of all-cause mortality
[70•, 71•, 73•], increasing the risk of death up to eightfold
[70•]. Mid-wall fibrosis therefore appears to be a direct marker
of the left ventricular decompensation in aortic stenosis and
may be of use in identifying patients whose ventricle are
starting to fail and who might benefit from prompt AVR.
Further research on this area is needed; indeed, EVoLVeD-
AS a multicentre randomised-controlled trial assessing the
benefit of early surgery in patients with advanced aortic ste-
nosis and mid-wall fibrosis on CMR is due to the start enroll-
ing patients next year.
Diffuse Fibrosis
The non-invasive assessment of diffuse fibrosis is more chal-
lenging. Its homogeneous nature means that it is missed on
LGE techniques, which rely on regions of normal myocardium
to generate contrast. However, the detection of diffuse fibrosis
is important because it is widely believed to be reversible [75]
and the precursor to irreversible forms of replacement fibrosis.
Myocardial T1 mapping techniques enable the calculation
of a specific T1 relaxation time (native T1) for each CMR
voxel which can then be displayed on a 2D map with colour
overlays applied for easier visual analysis. Multiple different
techniques have been developed (Table 1). Full examination
of these techniques is beyond the scope of this article, but
further information can be found in this recent review by
Moon et al. [76]. In brief, native T1 measurements can be
made without the need for contrast, an important potential
advantage especially in subjects with severe renal dysfunction
who are at risk of contrast-induced nephrogenic systemic fi-
brosis (NSF) [77]. GBCA can also be used to generate post-
contrast T1 maps as gadolinium shortens T1 relaxation times.
In principle, these images provide greater signal but they are
influenced by individual variation in gadolinium kinetics and
have suffered from poor reproducibility when studied in AS
populations [78•]. Importantly, these variations in kinetics can
be corrected using several approaches. The partition coeffi-
cient (λ) is calculated as a ratio of myocardial to blood post-
contrast T1 values, which improves reproducibility and cor-
rects for many confounders. At gadolinium contrast equilibri-
um, the contrast concentration in the blood and myocardium
should be equal. Calculating the blood volume of distribution
(1—haematocrit) enables the myocardial volume of distribu-
tion to be deduced, also termed the extracellular volume frac-
tion (ECV). Because ECV predominantly comprises collagen
and is increased in fibrotic states, it acts as a marker of myo-
cardial fibrosis, correlating closely with the collagen volume
fraction on histology [79–82].
Although native T1 and ECV have been extensively stud-
ied in the literature, results are mixed and interpretation is
confounded by heterogenous studied populations, variations
in T1 mapping sequence, CMR scanner, magnetic field
strength and analytical technique (e.g. inclusion or exclusion
of areas of LGE).
Native T1 values appear to correlate with histological myo-
cardial fibrosis [83, 84] as well as global longitudinal strain
Fig. 4 Cardiac magnetic
resonance imaging in a patient
with severe aortic stenosis.
Predominant asymmetrical
hypertrophy of the anteroseptum
is seen with associated patchy
mid-wall late gadolinium
enhancement (LGE, red arrows).
These areas are also identified
visually using native and post-
contrast T1 maps (white arrows)
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[84], LV mass, haemodynamic assessments of severity and
patient functional status [83]. However, its ability to differen-
tiate healthy patients from controls is dependent on the popu-
lation studied [78•, 83] with a significant degree of overlap in
T1 values between these groups particularly subjects with less
advanced stenosis. In a population of non-ischaemic dilated
cardiomyopathy patients, native T1 has recently been shown
to be an independent predictor of all-cause mortality and heart
failure events [85] although this has not been demonstrated in
aortic stenosis patients.
ECV
The extracellular volume fraction is used as a surrogate for the
extracellular space, which is expanded with collagen deposi-
tion in diffuse fibrosis. Our centre has demonstrated superior
intra- and inter-observer and scan-rescan variability in aortic
stenosis compared to the other T1 measures, and ECV corre-
lates with LV diastolic dysfunction [78•] and functional status
[86]. However, prognostic data is currently lacking. There is
also significant overlap between ECV values obtained in
healthy volunteers and AS patients, and normal ECV values
have been observed in a hypertensive population (another
condition characterised by LV pressure overload) [87].
Another disadvantage is that ECV measures fibrosis rela-
tive to the volume (or mass) of the left ventricle. Balanced
increases in both LVmass and diffuse fibrosis with progressive
aortic stenosis are therefore not detected using this approach.
In fact, an important study by Krayenbeuhl et al. involving
serial myocardial biopsies demonstrated that histological myo-
cardial fibrosis as a percentage of the myocardium (which is
estimated by ECV calculation on CMR) actually increased
early following aortic valve surgery as a result of significant
reduction in LVmass with no change in the amount of fibrosis.
However, the overall fibrous content (which can be estimated
on CMR by fibrosis volume; ECV × end-diastolic myocardial
volume) did eventually decrease at a later stage (repeat biopsy
an average of 70 months post AVR) [75]. This is partly sup-
ported by a recent CMR study which found that ECV did not
change at 6 months following AVR, whereas there was signif-
icant regression of cellular hypertrophy [86]. There is however
no CMR data regarding late regression of diffuse fibrosis mea-
sures. We believe the use of the fibrosis volume as a measure
of absolute fibrosis may better reflect disease progression and
be able to track changes across interval scans, although this
requires investigation in prospective studies.
Clinical Risk Score
CMR is an expensive technique with limited availability in
many centres. We have devised a clinical risk score [88] based
on five readily measured variables: age, sex, peak aortic valve
velocity, high sensitivity troponin I concentration and pres-
ence of LV strain pattern on ECG, which is highly predictive
of the presence of mid-wall replacement fibrosis on CMR and
mortality. Ultimately, this could be used clinically in place of
CMR imaging or as a screening tool for LV decompensation
in aortic stenosis.
Valve Assessment
CT imaging is able to detect macroscopic calcium deposits in
the aortic valve but is unable to identify fibrosis or lipid depo-
sition, which are key components in the stenotic valve. CMR
offers superior tissue characterisation as demonstrated in a
proof of concept study where 30 explanted aortic valves were
scanned ex-vivo and compared with histological analysis.
CMR showed excellent sensitivity and specificity for the iden-
tification of both mineralisation (calcification) and fibrosis,
with lower accuracy for lipid-rich tissues [89]. Although this
is an exciting field for further research, in vivo imaging with
this approach is not currently feasible due to leaflet motion.
Table 1 T1 mapping measures available for assessment of myocardial fibrosis
Measure Unit Calculation Advantages Limitations
Native T1 ms T1 relaxation curve No gadolinium requirement
(can use in severe renal failure)
T1 signal represented a composite of
myocardium and extracellular space
Post-contrast T1 ms T1 relaxation curve following
gadolinium administration
Improved sensitivity in identifying
myocardial fibrosis
Significant variability due to individual
variation in gadolinium kinetics and
time to imaging post-contrast injection
Partition coefficient (λ) Ratio Ratio of T1 signal change
(pre- and post-contrast) in
myocardium and blood pool
Excellent scan-rescan reproducibility Does not account for plasma volume of
distribution of gadolinium contrast
Extracellular volume
fraction (ECV)
% ECV= λ × (1—haematocrit) Excellent scan-rescan reproducibility.
Conceptually attractive measure
Gives a measure of relative fibrosis
which may not best track changes in
aortic stenosis
Fibrosis volume ml ECV× end-diastolic volume Quantitative measure of absolute
fibrosis volume
Limited evidence at current time
May require indexing to body size to
enable comparison between individuals
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Aortic Regurgitation
Echocardiography
TTE remains the first-line imaging modality in the investiga-
tion of patients with aortic regurgitation, allowing assessment
of mechanism, valve morphology and severity of regurgita-
tion as well as measures of LV remodelling and function.
Imaging of the aortic root and ascending aorta is essential,
although in patients with poor acoustic windows, cross-
sectional imaging may be required for accurate assessment.
The assessment of aortic regurgitation severity is more nu-
anced than aortic stenosis, requiring the integration of differ-
ent visual, semi-quantitative and quantitative parameters as
recommended by clinical guidelines [5, 6]. Visual assessment
of the valve leaflets allows appreciation of prolapse or non-
coaptation, whilst the length and width of the regurgitant jet
on colour Doppler gives a qualitative impression of severity.
Whilst useful, these measures correlate onlymodestly with the
following more objective measures of AR severity which also
require assessment [90].
Semiquantitative Parameters
Calculating the ratio of the regurgitant jet width to that of the
LVOT gives a semiquantitative measure of AR severity (se-
vere if >65 %) [91]. The vena contracta (the narrowest part of
the regurgitant jet) can also be measured, and a width of
>0.6 cm suggests severe AR. Both these techniques are limit-
ed by a single plane of assessment and the assumption of a
circular regurgitant orifice. 3D TTEmay therefore allow more
accurate measurements [92].
Doppler-Based Measures
Although continuous wave AR Doppler jet density is a poor
marker of severity, the rate of deceleration (pressure half-time,
PHT) is a useful adjunct to other measures. A value of
<200 ms is considered severe with measurements critically
dependent on obtaining an aligned Doppler signal. PHT is best
used in addition to other parameters as it is affected by LV
compliance, blood pressure and usually reduced in acute AR
of any severity. Doppler assessment of aortic flow direction is
highly useful where imaging windows allow. Holodiastolic
flow reversal in the descending aorta, especially when associ-
ated with an end-diastolic velocity of >20 cm/s, is specific but
not sensitive for severe AR [93].
Quantitative Parameters
Calculation of effective regurgitant orifice area (EROA) or
regurgitant volume (RV) is possible in some patients using
the flow-convergence zone (PISA) method, which is less
sensitive to loading conditions than other measures and also
useful if the jet is eccentric. It is however less well studied than
in mitral regurgitation, assumes a circular orifice (with a hemi-
spheric flow convergence zone) and is impossible to measure
in a substantial proportion of patients [90]. An alternative is
the regurgitant fraction (RF), which can be calculated by the
Doppler volumetric method. This involves comparing the sys-
temic stroke volume (calculated by assessing the flow over
either the mitral or pulmonary valves assuming no significant
valvular regurgitation) with the total stroke volume (calculated
from LVOT flow.) This is time-consuming and the potential
for compounding multiple small measurement errors can lead
to substantial overall inaccuracies. Again, the use of 3D TTE
may be superior in calculating regurgitant fraction [94].
LV Dimensions and Function
The response of the LV to chronic volume overload is cham-
ber dilatation and hypertrophy. Left ventricular end-systolic
diameter (LVESd) is an independent predictor of the develop-
ment of cardiac symptoms or LV dysfunction [95, 96] and the
risk of progression or mortality approaches 20 % when
LVESd >5.0 cm [97]. LV systolic impairment occurs late in
the disease process and is associated with poor prognosis [98]
which is improved following AVR [99]. Current clinical
guidelines advise valve intervention for asymptomatic severe
AR in the presence of significant LV dilatation (LVESd
>5.0 cm) or LV systolic impairment [5, 6]. Other measures
of LV function such as global strain and strain rate may detect
earlier decompensation, and further research on outcomes is
needed [100–103].
TOE
As with aortic valve replacement for aortic stenosis,
transoesophageal echocardiography is frequently used (with
significant variation between centres) both pre- and intraoper-
atively to aid in prosthesis sizing, confirm satisfactory pros-
thesis functioning and detect immediate post-operative com-
plications. In centres with appropriate expertise, TOE also
allows detailed assessment of valve morphology permitting
valve preserving repair procedures in selected patients, partic-
ularly those with aortic root aneurysms or regurgitant non-
calcified bicuspid valves [104].
CMR
As discussed, CMR provides the gold-standard assessment of
LV volumes and ejection fraction [105]. Perhaps unsurprising-
ly, therefore, left ventricular dilatation detected by CMR (end-
diastolic volume (EDV) >246ml) has shown strong predictive
ability for the future development of symptoms and need for
valve surgery in AR [106••]. However, CMR is also able to
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determine the aortic regurgitant volume to a high degree of
accuracy using phase-contrast velocity mapping. This map,
created in an orthogonal plane to that of aortic flow (usually
at the level of the sinotubular junction [107]), encodes flow to
each voxel and covers the whole cardiac cycle. It can therefore
be used to calculate both anterograde and retrograde flow
(and ultimately regurgitant volume and fraction, Fig. 5).
It shows superior reproducibility to echocardiography
[108] and excellent correlation with both TTE assess-
ment [109] and invasive measures of stroke volume
[110]. There is some debate as to the optimal cut-off in
the regurgitant fraction to define severe regurgitation. A
value of 50 % as used in TTE would seem logical, but
there is evidence of superior discrimination at a lower
value of 30 % [111] and a RF above 33 % strongly
predicted the need for surgery within 3 years in a series
of 113 patients [106••]. Although there are some techni-
cal reasons why a discrepancy may exist, further work is
required to corroborate this single centre study and to
demonstrate improvement in patient outcomes using this
more expensive imaging modality. However, there may
be a place for CMR assessment of aortic regurgitation in
clinical practice when there is diagnostic uncertainty as
to severity of regurgitation.
Conclusions
Aortic valve imaging is a rapidly expanding and exciting
field. Although transthoracic echocardiography has limi-
tations, it remains the first-line imaging modality of
choice. However, other techniques are emerging which
provide complimentary information and may aid clinical
decision-making. In particular, CT can quantify the cal-
cium burden in aortic stenosis as an alternative measure
of disease severity. CMR can quantify the aortic
regurgitant volume and provide detailed assessment of
the hypertrophic response whilst PET can directly mea-
sure disease activity in the valve. Further research is
required to investigate the role that these approaches
may play in the future, where incremental clinical benefit
to standard echocardiographic approaches will need to be
demonstrated.
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Fig. 5 Phase-contrast velocity mapping for aortic regurgitation
quantification. The slice location for through plane measurement is
shown on a three chamber still image (top) with a jet of aortic
regurgitation visible (white arrow). Through plane images are shown
(middle) in systole depicting magnitude (left) and flow (middle) and
diastole showing regurgitation in black (right). Regurgitant volume and
fraction can then be calculated from a time-flow curve (bottom). LV left
ventricle, Ao aorta, LA left atrium. Reproduced from Myerson et al.
[106••] with permission from Wolters Kluwer Health, Inc./Circulation
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